Navigation Links
Rotavirus vaccine developed in India demonstrates strong efficacy
Date:5/14/2013

the social innovation partnership and ensuring the highest standards for the vaccine.

The randomized, double-blind, placebo-controlled Phase III clinical trial enrolled 6,799 infants in India (aged six to seven weeks at the time of enrolment) at three sitesthe Centre for Health Research and Development, Society for Applied Studies (SAS) in New Delhi; Shirdi Sai Baba Rural Hospital, KEM Hospital Research Centre in Vadu, Pune; and Christian Medical College (CMC) in Vellore. The Clinical Operations Management Unit headed by Dr Nita Bhandari at SAS oversaw the day-to-day coordination and logistical complexities of this multi-site study and played a pivotal role in the conduct of this trial. The Principal Investigators were Dr Temsunaro Rongsen-Chandola at SAS, Dr Ashish Bavdekar at KEM, and Dr Gagandeep Kang at CMC.

The Data Safety Monitoring Board (DSMB), an independent group of experts established to protect the participating infants' rights and needs during the Phase III trial, determined that the trial met the highest standards for ethics and patient care and complied with international standards for good clinical practices.

Bharat Biotech previously announced a price of US$ 1.00/dose (or approximately INR 54/dose) for ROTAVAC and will soon file for registration of the vaccine in India. If licensed by the Drugs Controller General of India (DCGI), the vaccine will be a more affordable alternative to the rotavirus vaccines already on the market.

"With its low price and strong efficacy, ROTAVAC has the potential to significantly reduce the incidence of severe diarrhoea due to rotavirus among children in India," said Dr M.K. Bhan, Advisor to the Indian Academy of Pediatrics and former DBT Secretary.

The vaccine efficacy compares favourably with the efficacy of the currently licensed rotavirus vaccines in low-resource countries. The study results showed clear evidence of protection across different rotavirus strains and
'/>"/>

Contact: Allison Clifford
aclifford@path.org
202-669-7238
PATH
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Queens scientists seek vaccine for Pseudomonas infection
2. In search for a vaccine, IU biologist receives $2.3 million to explore chlamydia genomics
3. Scripps Research Institute scientists find promising vaccine targets on hepatitis C virus
4. SFU HIV/AIDS vaccine research gets financial boost
5. Researchers identify Achilles heel of dengue virus, target for future vaccines
6. AAPS National Biotechnology Conference to highlight innovative vaccines
7. Army study: DNA vaccine and duck eggs protect against hantavirus disease
8. Sensitive test helps improve vaccine safety
9. Overweight? Theres a vaccine for that
10. Vaccine and antibiotics stabilized so refrigeration is not needed -- NIH study
11. Scripps Research Institute wins $77 million to develop AIDS vaccine center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/12/2015)... , March 12, 2015 WHEN:Tuesday, March ... Registration here: http://bit.ly/1G7Os0L . SPEAKERS: , Frost ... SeshagiriPhoto - http://photos.prnewswire.com/prnh/20150311/181111 Biometric ... to compete in several different markets and industries. ... currently witnessing an uptrend. Join ...
(Date:3/10/2015)... Colo. , March 10, 2015 ... Flight "Personalized Medicine in Human Space ... and Thomas J. Goodwin , Ph.D. was recently ... of the past two years. Specifically, "Personalized ... most downloaded scientific papers published in 2013 and 2014 ...
(Date:3/4/2015)... , Mar. 04, 2015 Research and Markets ... addition of the "Global Biometrics Market Forecast ... The market for biometric authentication systems ... around 14% till 2020 The driving ... increasing security needs, government projects and constant development ...
Breaking Biology News(10 mins):Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3
... A new surgical procedure for head and neck cancer ... accuracy for surgeons and reduced post-operative pain for patients. ... have shown it lessens the scarring, breathing problems and ... and neck cancers, said William Carroll, M.D., a scientist ...
... team of French and German researchers report in the ... http://www.fasebj.org ) that people with limb-girdle muscular dystrophy are ... to prevent the loss of muscle tissue. By targeting ... protein, scientists could develop new drugs to stop muscle ...
... Internationally respected scientists will gather next week for a ... a mind and to emphasize the need for $4 billion ... years. Presented by Great Ape Trust of Iowa, Decade ... recognized research pioneers from a variety of disciplines May 7-9 ...
Cached Biology News:New surgery improves head and neck cancer treatment 2Researchers discover molecular basis of a form of muscular dystrophy 2Decade of the Mind symposium in Iowa to emphasize need for $4 billion in federal support 2Decade of the Mind symposium in Iowa to emphasize need for $4 billion in federal support 3Decade of the Mind symposium in Iowa to emphasize need for $4 billion in federal support 4
(Date:3/30/2015)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), a ... of innovative therapeutics addressing cancer and other unmet medical ... on China , announced today that ... the Company,s application to conduct a Phase 2 global ... for its proprietary drug candidate ENMD-2076.  ...
(Date:3/30/2015)... 2015 Immunocore Limited, a ... treat cancer, viral infections and autoimmune disease, today ... Bell , the Regius Professor of Medicine at ... the Strategic Coordination of Health Research, to its ...      (Photo: http://photos.prnewswire.com/prnh/20150330/736483 ) , ...
(Date:3/29/2015)... March 29, 2015  Caris Life Sciences® ... in small cell cervical cancer (SCCC) that ... Intelligence®, the company,s panomic, comprehensive tumor profiling ... which may explain sensitivities and resistance to ... of certain biomarkers may guide treatment strategies ...
(Date:3/27/2015)... , 27. März 2015  Peter ... in Biomedical Science für seine bahnbrechende Arbeit ... zwischen Zellkompartimenten transportiert werden, sowie für die ... zur Reaktion auf Stress nutzen, der mit ... Walter ist Professor für Biochemie an der ...
Breaking Biology Technology:CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Immunocore Appoints Professor Sir John Bell to its Board of Directors 2Immunocore Appoints Professor Sir John Bell to its Board of Directors 3Immunocore Appoints Professor Sir John Bell to its Board of Directors 4Immunocore Appoints Professor Sir John Bell to its Board of Directors 5Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 2Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 4
... China Medical Technologies, Inc.,(the "Company") (Nasdaq: ... company,that develops, manufactures and markets advanced in-vitro diagnostic ... development of two,proprietary molecular diagnostic kits for the ... patients with non-small cell lung,cancer ("NSCLC"). The Company ...
... Inc. (OTC Bulletin Board: SYMD) announced today that it ... bioresorbable membrane intended to prevent post-operative adhesions in nasal ... nasal and sinus procedures performed annually in the United ... Robert P. Hickey, SyntheMed,s President & CEO stated, "SinusShield ...
... November 25, ... ... https://www.atlanticabioenergy.com/ , ... ST.ANDREWS BY-THE-SEA, NB, Nov. 19 /PRNewswire/ - The global forestry industry is rapidly changing and it ...
Cached Biology Technology:China Medical Technologies Completes the Development of EGFR Molecular Diagnostic Kits 2SyntheMed Announces FDA Clearance of SinusShield(TM) 2Media Advisory - Atlantica BioEnergy Task Force Leaders' Roundtable 2
Mouse monoclonal antibody to ACP2 - acid phosphatase 2, lysosomal...
Mouse monoclonal antibody to DCAMKL2 - doublecortin and CaM kinase-like 2...
... new IKATUBE ULTRA TURRAX Tube Disperser System from ... system. It offers a cleaner, safer, and more ... processes sample volumes from 2 to 15 ml ... researchers can choose one of 4 different tube ...
... Wyatt Technology's family of light scattering instruments. ... temperature chromatograph and enables you to get ... The HTmD is easily installed in the ... Alliance 2000 device and enables you to ...
Biology Products: